Jeffrey Guptill, MD, MA, MHS
Dr. Guptill is Associate Professor of Neurology at Duke University School of Medicine and serves as Director of the Duke Early Phase Clinical Research Unit which is the phase 1 and proof-of-concept clinical trial unit at Duke. He completed a master’s degree in Anatomy & Neurobiology at Boston University School of Medicine and received his medical school training at Medical College of Virginia. He then completed the adult neurology residency program at Duke University Medical Center, followed by neuromuscular medicine/EMG and advanced neuromuscular disease fellowships, also at Duke. He was a fellow at the Duke Clinical Research Institute (DCRI) and finished a Neurology Drug Development Fellowship cosponsored by UCB Biosciences, Inc, University of North Carolina-Chapel Hill, DCRI, and the Hamner Institutes.
Dr. Guptill’s research interests include the development of diagnostic and predictive biomarkers and conducting clinical trials of novel therapeutics for the treatment of inflammatory neuromuscular diseases such as myasthenia gravis. His goal is to understand why available treatments do not work for some patients and to identify targets for developing new therapies to help patients with these debilitating diseases. His research is supported by NIH, private foundations, and the pharmaceutical industry. He leads the NeuroIMmunology BiosampLE (NIMBLE) network – a multisite clinical research network and biosample repository for rare neuromuscular diseases, particularly myasthenia gravis. He is also a member of the executive committee for the NIH funded rare disease clinical research network for myasthenia gravis (MGNet), where he chairs the natural history study and career enhancement core. He currently serves as chair of the Myasthenia Gravis Foundation of America Medical Scientific Advisory Board.